An analysis of the utility of plasma immunoreactive estrogen measurements in determining delivery time of gravidas with a fetus considered at high risk.
Although maternal estrogen excretion and plasma estrogen levels are widely used to assess fetal health, the utility of these tests in lowering perinatal mortality rates has not been established. In order to ascertain if, with the help of plasma immunoreactive estrogen measurements, a reduction in perinatal deaths could be achieved, a population of women with a fetus at high risk were randomly divided into two groups and studied prospectively: in 315 gravidas, the estrogen results were reported (Group A); in 307, they were not reported (Group B). Nine perinatal deaths occurred in Group A, 10 in Group B. Ten Group B women whose infant ultimately did well would have been delivered 28 days or more prematurely if management had been based solely on the basis of abnormal immunoreactive estrogen levels. Measurement of estrogen levels is of little value in management of women with a fetus at risk; it may even lead to erroneous premature delivery.
D000293:Adolescent; D000328:Adult; D002585:Cesarean Section; D036861:Delivery, Obstetric; D004967:Estrogens / Q000097:blood* / Q000652:urine; D005260:Female; D005313:Fetal Death; D005865:Gestational Age; D006801:Humans; D006973:Hypertension / Q000150:complications; D007118:Immunoassay; D007226:Infant Mortality; D007231:Infant, Newborn; D007751:Labor, Induced; D011247:Pregnancy; D011248:Pregnancy Complications
D004967:Estrogens